Planta Med 2010; 76(6): 561-565
DOI: 10.1055/s-0029-1240600
Pharmacology
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

Inhibitory Activity of a Phytochemically Characterized Fraction from Streptocaulon juventas on Lung Cancer in Nude Mice

Na Han1 , Jingyu Yang2 , Linwei Li2 , Bin Xiao1 , Sha Sha2 , Lequan Tran3 , Jun Yin1 , Chunfu Wu2
  • 1Department of Pharmacognosy, Shenyang Pharmaceutical University, Shenyang, China
  • 2Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China
  • 3Department of Sciences, National University of HCM, HoChiMinh, Vietnam
Weitere Informationen

Publikationsverlauf

received March 2, 2009 revised July 4, 2009

accepted October 21, 2009

Publikationsdatum:
16. November 2009 (online)

Abstract

In the present study, a 75 % ethanol extract of Streptocaulon juventas (SJ), which had a strong inhibitory effect on the proliferation of human lung A549 adenocarcinoma cells, was subjected to bioassay-guided fractionation. The most active fraction (SJF) was obtained using a macroreticular resin column followed by a silica-gel column. Then its in vivo effect on lung cancer was investigated in athymic nude mice with A549 tumors while its effects on body weight, blood biochemical indicators, and organ indices were monitored. The results showed that SJF inhibited the tumor growth significantly at day 10 and day 15 during treatment without physical side effects. Following HPLC and NMR spectrometry, the main components of SJF were identified as digitoxigenin, periplogenin, and periplogenin glucoside.

References

  • 1 Ueda J Y, Tezuka Y, Banskota A H, Tran Q L, Tran Q K, Harimaya Y, Saiki I, Kadota S. Antiproliferative activity of Vietnamese medicinal plants.  Biol Pharm Bull. 2002;  25 753-760
  • 2 Quin J, Engle D, Litwiller A, Peralta E, Grasch A, Boley T, Hazelrigg S. Vitamin E succinate decreases lung cancer tumor growth in mice.  J Surg Res. 2005;  127 139-143
  • 3 Chen Y L, Lin S Z, Chang J Y, Cheng Y L, Tsai N M, Chen S P, Chang W L, Harn H J. In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells.  Biol Pharm. 2006;  72 308-319
  • 4 Li M, Li W D. Liver injury in mice induced by ConA.  Chin J Complement Med. 2008;  18 14-15
  • 5 Yu D Q, Yang J S, Xie J X. NMR analysis. Analytical chemistry handbook, Vol. 5. Beijing; Chemistry and Industry Press 1989: 811-812
  • 6 Kawaguchi K, Hirotani M, Fuluya T. Biotransformation of digitoxigenin by cell suspention cultures of Strophanthus amboensis.  Phytochemistry. 1988;  27 3475-3479
  • 7 Kelland L R. “Of mice and men”: values and liabilities of the athymic nude mouse model in anticancer drug development.  Eur J Cancer. 2004;  40 827-836
  • 8 Sausville E A, Newell D R. Preclinical models in cancer drug discovery and development.  Eur J Cancer. 2004;  40 783-784
  • 9 Peterson J K, Houghton P J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.  Eur J Cancer. 2004;  40 837-844
  • 10 Peterson J K, Tucker C, Favours E, Cheshire P J, Creech J, Billups C A, Smykla R, Lee F Y F, Houghton P J. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.  Clin Cancer Res. 2005;  11 6950-6958
  • 11 Tan M, Fang H B, Tian G L, Houghton P J. Repeated-measures models with constrained parameters for incomplete data in tumor xenograft experiments.  Stat Med. 2005;  24 109-119
  • 12 Graham C, Tucker C, Creech J, Favours E, Billups C A, Liu T, Fouladi M, Freeman B B, Stewart C F, Houghton P J. Evaluation of the antitumor efficacy, pharmacokinetics and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.  Clin Cancer Res. 2006;  12 223-234
  • 13 Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, White K, Knight J, Demchik L, Jones J, Jones L, Lisow L. In vivo methods for screening and preclinical testing. Teicher B Anticancer drug development guide: preclinical screening, clinical trials and approval. Totowa; Humana Press, Inc. 1997: 75-99
  • 14 Plowman J, Dykes D J, Hollingshead M, Simpson-Herren L, Alley M C. Human tumor xenograft models in NCI drug development. Teicher B Anticancer drug development guide: preclinical screening, clinical trials and approval. Totowa; Humana Press, Inc. 1998: 101-125
  • 15 Teicher B A. Preclinical models for high-dose therapy. Teicher B Anticancer drug development guide: preclinical screening, clinical trials and approval. Totowa; Humana Press, Inc. 1998: 145-182
  • 16 Corbett T H, Polin L, Roberts B J, Lawson A J, Leopold III W R, White K, Kushner J, Paluch J, Hazeldine S, Moore R, Rake J, Horwitz J P. Transplantable syngeneic rodent tumors: solid tumors in mice. Teicher BA Tumor models in cancer research. Totowa; Humana Press, Inc. 2002: 41-72
  • 17 Ueda J Y, Tezuka Y, Banskota A H, Tran Q L, Tran Q K, Saiki I, Kadota S. Constituents of the Vietnamese medicinal plants Streptocaulon juventas and their antiproliferative activity against the human HT-1080 fibrosarcoma cell line.  J Nat Prod. 2003;  66 1427-1433
  • 18 Steyn P S, Heerden van F R. Bufadienolides of plant and animal origin.  Nat Prod Rep. 1998;  15 397-413

Prof. Jun Yin

Department of Pharmacognosy
Shenyang Pharmaceutical University

103 Wenhua Road

110016 Shenyang

China

Telefon: + 86 24 23 98 64 91

Fax: + 86 24 23 98 64 60

eMail: yinjun2002@yahoo.com